GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cronos Group Inc (TSX:CRON) » Definitions » EV-to-Revenue

Cronos Group (TSX:CRON) EV-to-Revenue : 3.15 (As of May. 01, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Cronos Group EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Cronos Group's enterprise value is C$373.1 Mil. Cronos Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was C$118.5 Mil. Therefore, Cronos Group's EV-to-Revenue for today is 3.15.

The historical rank and industry rank for Cronos Group's EV-to-Revenue or its related term are showing as below:

TSX:CRON' s EV-to-Revenue Range Over the Past 10 Years
Min: -2.59   Med: 37.29   Max: 943.97
Current: 3.15

During the past 10 years, the highest EV-to-Revenue of Cronos Group was 943.97. The lowest was -2.59. And the median was 37.29.

TSX:CRON's EV-to-Revenue is ranked worse than
62.3% of 1024 companies
in the Drug Manufacturers industry
Industry Median: 2.35 vs TSX:CRON: 3.15

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-01), Cronos Group's stock price is C$4.05. Cronos Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.31. Therefore, Cronos Group's PS Ratio for today is 13.06.


Cronos Group EV-to-Revenue Historical Data

The historical data trend for Cronos Group's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cronos Group EV-to-Revenue Chart

Cronos Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.04 25.75 7.14 1.00 -0.86

Cronos Group Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 -1.37 -1.11 -0.89 -0.86

Competitive Comparison of Cronos Group's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cronos Group's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cronos Group's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cronos Group's EV-to-Revenue falls into.



Cronos Group EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Cronos Group's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=373.121/118.488
=3.15

Cronos Group's current Enterprise Value is C$373.1 Mil.
Cronos Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$118.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cronos Group  (TSX:CRON) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Cronos Group's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=4.05/0.31
=13.06

Cronos Group's share price for today is C$4.05.
Cronos Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.31.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cronos Group EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cronos Group's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Cronos Group (TSX:CRON) Business Description

Traded in Other Exchanges
Address
111 Peter Street, Suite 300, Toronto, ON, CAN, M5V 2H1
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S. the company has an option to acquire 10.5% of U.S. multistate operator PharmaCann upon easing of federal prohibition.